


Robeco Healthy Living D EUR

Robeco Healthy Living is an actively managed sub-fund that invests globally in companies that promote good health and well-being and contribute to an efficient healthcare system. The selection of these stocks is based on fundamental analysis. The Sub-fund has sustainable investment as its objective, within the meaning of Article 9 of the Regulation (EU) 2019/2088 of 27 November 2019 on Sustainability-related disclosures in the financial sector. The strategy integrates sustainability criteria as part of the stock selection process and through a theme-specific sustainability assessment. The portfolio is built on the basis of an eligible investment universe that includes companies whose business models contribute to the thematic investment objectives. The assessment regarding relevant SDGs uses an internally developed framework, more information on which can be obtained at www.robeco.com/si. The Sub-fund also aims to achieve a better return than the index.



David Kägi, Alyssa Cornuz CFA
Fund manager since 01-03-2020

Performance

	Fund	Index
1 m	-0.23%	0.33%
3 m	-3.50%	5.15%
Ytd	-11.73%	0.65%
1 Year	-15.23%	9.39%
2 Years	-0.41%	15.53%
3 Years	-1.47%	12.65%
5 Years	1.36%	13.38%
10 Years	3.34%	11.16%
Since 04-2007	4.92%	8.44%

Annualized (for periods longer than one year)

Note: due to a difference in measurement period between the fund and the index, performance differences may arise. For further info, see last page.

Calendar year performance

	Fund	Index
2024	8.14%	26.60%
2023	4.10%	19.60%
2022	-15.60%	-12.78%
2021	22.35%	31.07%
2020	-0.92%	6.33%
2022-2024	-1.69%	9.71%
2020-2024	2.87%	12.98%

Annualized (years)

Index

MSCI World Index TRN

General facts

Morningstar	★★★
Type of fund	Equities
Currency	EUR
Total size of fund	EUR 202,003,218
Size of share class	EUR 43,813,333
Outstanding shares	180,816
1st quotation date	29-10-2020
Close financial year	31-12
Ongoing charges	1.71%
Daily tradable	Yes
Dividend paid	No
Ex-ante tracking error limit	-
Management company	Robeco Institutional Asset Management B.V.


Sustainability profile

- Exclusions++
- ESG Integration
- Voting
- ESG Target

For more information on exclusions see <https://www.robeco.com/exclusions/>
For more information on target universe methodology see <https://www.robeco.com/si>

Performance

Indexed value (until 31-08-2025) - Source: Robeco



Performance

Based on transaction prices, the fund's return was -0.23%.

In August, the Healthy Living Fund slightly underperformed versus the broad global benchmark and its investable universe. Two of the fund's four clusters generated positive returns. Healthcare Efficiency was the strongest performer, followed by Healthy Lifestyles. Healthy Nutrition delivered negative returns while Therapeutics was only slightly negative. At the individual stock level, the biggest positive contributor in August was managed care player UnitedHealth, which rose on news that Warren Buffett's Berkshire Hathaway had taken a stake in the company. In July, the company had reinstated a full year guidance, providing highly needed visibility to the market, after a disappointing second-quarter earnings report. The largest negative contributor in August was protein shake company Belling Brands, which saw a sharp share price correction despite delivering a strong quarter, with double-digit percentage growth in the consumption of its ready-to-drink shakes. Management's refusal to provide guidance for the next financial year, starting on October 1st, and statements on heightened competition spooked the market.

Market development

In August, the global market delivered positive returns, driven by the materials, healthcare and consumer discretionary sectors. Both the healthcare and consumer staples sectors, which together account for three quarters of the Healthy Living portfolio, generated positive returns and outperformed the broader market. The information technology sector, which is the largest sector in the MSCI World Index, underperformed, while the utilities sector was the only sector which generated negative returns in the month. After strong share price corrections in managed care companies as well as obesity drug manufacturer Novo Nordisk, which had weighed heavily on global healthcare sector performance in July, the subsequent rebound in their share prices supported strong performance of the sector in August. Similarly, within consumer staples, the reversal in share price development of heavy weights such as Nestlé and Procter & Gamble supported sector performance.

Expectation of fund manager

The risks to economic growth have increased due to inflation, higher interest rates, geopolitical tensions and the economic imbalances in China. In addition, the tariff announcements by the new US president have created almost unprecedented uncertainty in the business environment, which may reduce corporate investments and consumer confidence going forward. It will therefore be even more important to focus on solid business fundamentals, pricing power and quality. We remain constructive on the mid to long-term potential of the equity markets and are making use of current market conditions to further solidify our positions in companies that have very strong long-term business prospects. The pandemic has accelerated changes necessary to build more robust and sustainable economies. It has also made individuals more inclined to adopt a healthier lifestyle. The Healthy Living portfolio of sustainable companies is well positioned to benefit from these changes in the longer run.

Top 10 largest positions

AstraZeneca - innovative global large pharmaceutical company; Danone – leading provider of fresh dairy products and plant-based foods globally; Grifols – manufacturer of blood plasma products; Medtronic – diversified MedTech company with a focus on cardiovascular and neurological solutions; Maximus – operator of government health and human services programs; Siemens Healthineers – medical equipment and hospital diagnostics company; Agilent Technologies - provider of analytical instruments, tests and reagents for life science applications; Haleon – global consumer health company with a focus on oral health and OTC medicines; Thermo Fisher Scientific - provider of analytical equipment and tests for the life science industry; DSM-Firmenich - innovative ingredients provider for nutrition, health and personal care

Fund price

31-08-25	EUR	242.31
High Ytd (30-01-25)	EUR	288.14
Low Ytd (06-08-25)	EUR	234.12

Fees

Management fee	1.50%
Performance fee	None
Service fee	0.16%

Legal status

Investment company with variable capital incorporated under Luxembourg law (SICAV)
 Issue structure Open-end
 UCITS V Yes
 Share class D EUR
 This fund is a subfund of Robeco Capital Growth Funds, SICAV.

Registered in

Austria, Belgium, Denmark, Finland, France, Germany, Ireland, Italy, Liechtenstein, Netherlands, Norway, Portugal, Singapore, Spain, Sweden, Switzerland, United Kingdom

Currency policy

The fund is allowed to pursue an active currency policy to generate extra returns and can engage in currency hedging transactions.

Risk management

Risk management is fully integrated into the investment process to ensure that positions always meet predefined guidelines.

Dividend policy

In principle the fund does not intend to distribute dividend and so both the income earned by the fund and its overall performance are reflected in its share price.

Fund codes

ISIN	LU2146189407
Bloomberg	RSSLDE LX
WKN	A2QBUN
Valoren	55753607

Top 10 largest positions

Holdings

AstraZeneca PLC
 Danone SA
 Grifols SA Pref
 Medtronic PLC
 Maximus Inc
 Siemens Healthineers AG
 Agilent Technologies Inc
 Haleon PLC
 Thermo Fisher Scientific Inc
 DSM-Firmenich AG
Total

Sector	%
Pharmaceuticals	4.72
Food Products	4.07
Biotechnology	3.87
Health Care Equipment & Supplies	3.86
Professional Services	3.48
Health Care Equipment & Supplies	3.44
Life Sciences Tools & Services	3.32
Pharmaceuticals	3.24
Life Sciences Tools & Services	3.24
Chemicals	3.13
Total	36.37

Top 10/20/30 weights

TOP 10	36.37%
TOP 20	64.53%
TOP 30	86.82%

Statistics

	3 Years	5 Years
Tracking error ex-post (%)	8.77	8.33
Information ratio	-1.42	-1.23
Sharpe ratio	-0.24	0.13
Alpha (%)	-8.12	-6.12
Beta	0.65	0.71
Standard deviation	11.33	12.20
Max. monthly gain (%)	6.12	7.61
Max. monthly loss (%)	-7.32	-7.32

Above mentioned ratios are based on gross of fees returns

Hit ratio

	3 Years	5 Years
Months outperformance	12	23
Hit ratio (%)	33.3	38.3
Months Bull market	25	38
Months outperformance Bull	8	13
Hit ratio Bull (%)	32.0	34.2
Months Bear market	11	22
Months Outperformance Bear	4	10
Hit ratio Bear (%)	36.4	45.5

Above mentioned ratios are based on gross of fees returns.

Changes

This share class shows performance information prior to its launch date. On the launch date of this share class, the fund absorbed Multipartner SICAV - Robeco Sustainable Healthy Living Fund. Performance prior to the launch date has been simulated on the basis of the past performance of the absorbed fund that had similar investment policy and applied higher or comparable charges.

Asset Allocation

Asset allocation		
Equity		99.0%
Cash		1.0%

Sector allocation

The fund invests in companies benefiting from structural growth aligned with the Healthy Living trend. The strategy aims to capture investment opportunities linked to health promotion, disease prevention and effective treatment of chronic illness. As a result, the portfolio is invested mostly in the healthcare, consumer discretionary, consumer staples, materials, industrials and information technology sectors.

Sector allocation			Deviation index	
Health Care Equipment & Supplies		20.9%		18.9%
Food Products		12.9%		12.0%
Life Sciences Tools & Services		11.9%		11.2%
Pharmaceuticals		9.4%		5.5%
Chemicals		8.1%		6.7%
Personal Products		7.4%		6.9%
Biotechnology		6.2%		4.8%
Professional Services		6.0%		5.1%
Health Care Providers & Services		5.3%		4.1%
Textiles, Apparel & Luxury Goods		4.5%		3.8%
Hotels, Restaurants & Leisure		3.0%		1.2%
Food & Staples Retailing		1.5%		-0.2%
Other		2.8%		-80.0%

Regional allocation

The fund is currently 53% exposed to Europe, 44% to the Americas and 3% to Asia.

Regional allocation			Deviation index	
Europe		52.6%		36.5%
America		44.9%		-30.5%
Asia		2.5%		-5.7%
Middle East		0.0%		-0.3%

Currency allocation

The fund does not engage in currency hedging transactions.

Currency allocation			Deviation index	
U.S. Dollar		45.2%		-27.2%
Euro		24.9%		16.3%
Pound Sterling		13.7%		10.1%
Swiss Franc		5.3%		3.0%
Norwegian Kroner		4.6%		4.5%
Japanese Yen		2.5%		-3.0%
Mexico New Peso		2.2%		2.2%
Danish Kroner		1.5%		1.0%
Canadian Dollar		0.0%		-3.3%
Hong Kong Dollar		0.0%		-0.5%
Israeli Shekel		0.0%		-0.2%
Singapore Dollar		0.0%		-0.4%
Other		0.0%		-2.5%

ESG Important information

The sustainability information in this factsheet can help investors integrate sustainability considerations in their process. This information is for informational purposes only. The reported sustainability information may not at all be used in relation to binding elements for this fund. A decision to invest should take into account all characteristics or objectives of the fund as described in the prospectus. The prospectus is available on request and free of charge on the Robeco website.

Sustainability

The fund's sustainable investment objective is to promote good health and well-being and contributing to an efficient healthcare system. Healthy living and sustainability considerations are incorporated in the investment process by the means of a target universe definition, exclusions, ESG integration, and voting. The fund only invests in companies that have a significant thematic fit as per Robeco's thematic universe methodology. Through screening on both Robeco's internally developed SDG Framework and Robeco's exclusion policy, the fund does not invest in issuers that have a negative impact on the SDGs, are in breach of international norms or where products have been deemed controversial. Financially material ESG factors are integrated in the bottom-up fundamental investment analysis to assess existing and potential ESG risks and opportunities. In addition, where a stock issuer is flagged for breaching international standards in the ongoing monitoring, the issuer will become subject to exclusion. Lastly, the fund makes use of shareholder rights and applies proxy voting in accordance with Robeco's proxy voting policy.



For more information please visit the sustainability-related disclosures.

The index used for all sustainability visuals is based on MSCI World Index TRN.

SDG Impact Alignment

This distribution across SDG scores shows the portfolio weight allocated to companies with a positive, negative and neutral impact alignment with the Sustainable Development Goals (SDG) based on Robeco's SDG Framework. The framework utilizes a three-step approach to assess a company's impact alignment with the relevant SDGs and assign a total SDG score. The score ranges from positive to negative impact alignment with levels from high, medium or low impact alignment. This results in a 7-step scale from -3 to +3. For comparison, index figures are provided alongside that of the portfolio. Only holdings mapped as corporates are included in the figures.


Use of the United Nations Sustainable Development Goals (SDG) logos, including the colour wheel, and icons shall only serve explanatory and illustrative purposes and may not be interpreted as an endorsement by the United Nations of this entity, or the product(s) or service(s) mentioned in this document. The opinions or interpretations shown in this document hence do not reflect the opinion or interpretations of the United Nations.



Source: Robeco. Data derived from internal processes.

Sustainalytics ESG Risk Rating


The Portfolio Sustainalytics ESG Risk Rating chart displays the portfolio's ESG Risk Rating. This is calculated by multiplying each portfolio component's Sustainalytics ESG Risk Rating by its respective portfolio weight. The Distribution across Sustainalytics ESG Risk levels chart shows the portfolio allocations broken into Sustainalytics' five ESG risk levels: negligible (0-10), low (10-20), medium (20-30), high (30-40) and severe (40+), providing an overview of portfolio exposure to the different ESG risk levels. Index scores are provided alongside the portfolio scores, highlighting the portfolio's ESG risk level compared to the index. Only holdings mapped as corporates are included in the figures.



Source: Copyright ©2025 Sustainalytics. All rights reserved.

Environmental Footprint

Environmental footprint expresses the total resource consumption of the portfolio per mUSD invested. Each assessed company's footprint is calculated by normalizing resources consumed by the company's enterprise value including cash (EVIC). We aggregate these figures to portfolio level using a weighted average, multiplying each assessed portfolio constituent's footprint by its respective position weight. For comparison, index footprints are shown besides that of the portfolio. The equivalent factors that are used for comparison between the portfolio and index represent European averages and are based on third-party sources combined with own estimates. As such, the figures presented are intended for illustrative purposes and are purely an indication. Only holdings mapped as corporates are included in the figures.



Source: Robeco data based on Trucost data. *

* Source: S&P Global Market Intelligence data © Trucost 2025. All rights in the Trucost data and reports vest in Trucost and/or its licensors. Neither S&P Global Market Intelligence, nor its affiliates, nor its licensors accept any liability for any errors, omissions or interruptions in the Trucost data and/or reports. No further distribution of the Data and/or Reports is permitted without S&P Global Market Intelligence's express written consent. Reproduction of any information, data or material, including ratings is prohibited. The content is not a recommendation to buy, sell or hold such investment or security, nor does it address suitability of an investment or security and should not be relied on as investment advice.

Engagement

Robeco distinguishes between three types of engagement. Value Engagement focuses on long-term issues that are financially material and/or are causing adverse sustainability impacts. The themes can be broken into Environmental, Social, Governance, or Voting-related. SDG Engagement aims to drive a clear and measurable improvement in a company's SDG contribution. Enhanced engagement is triggered by misconduct and focuses on companies severely breaching international standards. The report is based on all companies in the portfolio for which engagement activities have taken place during the past 12 months. Note that companies may be under engagement in multiple categories simultaneously. While the total portfolio exposure excludes double counting, it may not equal the sum of individual category exposures.

	Portfolio exposure	# companies engaged with	# activities with companies engaged with
Total (* excluding double counting)	29.15%	12	62
Environmental	4.24%	2	7
Social	0.00%	0	0
Governance	16.78%	6	27
Sustainable Development Goals	17.87%	8	27
Voting Related	3.21%	1	1
Enhanced	0.00%	0	0

Source: Robeco. Data derived from internal processes.

Exclusions

The Exclusions charts display the degree of adherence to exclusion applied by Robeco. For reference, index exposures are shown beside that of the portfolio. Thresholds are based on revenues unless otherwise indicated. For more information about the exclusion policy and which level applies, please refer to the Exclusion Policy and Exclusion List available on Robeco.com.



Source: We use several data sources such as Sustainalytics, RSPO (Roundtable on Sustainable Palm Oil), World Bank, Freedom House, Fund for Peace and International Sanctions; further policy document available [Exclusion Policy](#)

Investment policy

Robeco Healthy Living is an actively managed sub-fund that invests globally in companies that promote good health and well-being and contribute to an efficient healthcare system. The selection of these stocks is based on fundamental analysis. The Sub-fund has sustainable investment as its objective, within the meaning of Article 9 of the Regulation (EU) 2019/2088 of 27 November 2019 on Sustainability-related disclosures in the financial sector. The strategy integrates sustainability criteria as part of the stock selection process and through a theme-specific sustainability assessment. The portfolio is built on the basis of an eligible investment universe that includes companies whose business models contribute to the thematic investment objectives. The assessment regarding relevant SDGs uses an internally developed framework, more information on which can be obtained at www.robeco.com/si. The Sub-fund also aims to achieve a better return than the index.

The fund has sustainable investment as its objective within the meaning of Article 9 of the European Sustainable Finance Disclosure Regulation. The fund aims to mitigate the rising incidence of lifestyle diseases and increasing healthcare costs, by investing in companies that provide technologies, products or services, medical treatments linked to the prevention of disease and reducing the spread of infectious diseases. This is done by investing in companies that mainly advance the following UN Sustainable Development Goals (UN SDGs): Good health and well-being, Zero Hunger, and Clean water and sanitation. The fund integrates ESG (Environmental, Social and Governance) factors in the investment process and applies Robeco's Good Governance policy. The fund applies sustainability indicators, including but not limited to, normative, activity-based and region-based exclusions, and proxy voting.

Fund manager's CV

David Kägi is Portfolio Manager of the Robeco Healthy Living strategy and member of the Thematic Investing team. Before joining Robeco in 2019, he worked as a Buy-Side analyst covering the global healthcare sector for Bank J. Safra Sarasin in Zurich, first for Private Banking, then for Asset Management. There, he also managed the Demography Health basket certificate for Bank J. Safra Sarasin. After some years in biomedical research following his PhD, he started his career in the financial industry in 1999 as a Healthcare Analyst at the investment company BT&T, followed by a position as an Investment Analyst for private biotechnology companies with Schweizerhall Management AG in Zurich. David holds a Master in Biochemistry and a PhD in T-cell Immunology both from the ETH Zurich. Alyssa Cornuz is Co-Portfolio Manager of the Robeco Healthy Living strategy and member of the Thematic Investing team. She is also the Deputy Portfolio Manager for the Fashion Engagement Fund and covers sportswear, off-price and cosmetics, amongst other, for the strategy. She joined in 2021 from Credit Suisse, where she was a Fund Selection Analyst covering ESG and impact funds. Until the end of 2019, she worked as a Fundamental Equity Analyst at Nordea for their Global Climate and Environment Fund. She started her career in 2016 at UBS in the Portfolio Advisory and European Equity team. Alyssa holds a Master of Science in Finance from HEC Lausanne and is a CFA® Charterholder.

Fiscal product treatment

The fund is established in Luxembourg and is subject to the Luxembourg tax laws and regulations. The fund is not liable to pay any corporation, income, dividend or capital gains tax in Luxembourg. The fund is subject to an annual subscription tax ('tax d'abonnement') in Luxembourg, which amounts to 0.05% of the net asset value of the fund. This tax is included in the net asset value of the fund. The fund can in principle use the Luxembourg treaty network to partially recover any withholding tax on its income.

Sustainability images

The figures shown in the sustainability visuals are calculated on subfund level.

MSCI disclaimer

Source MSCI. MSCI makes no express or implied warranties or representations and shall have no liability whatsoever with respect to any MSCI data contained herein. The MSCI data may not be further redistributed or used as a basis for other indices or any securities or financial products. This report is not approved, endorsed, reviewed or produced by MSCI. None of the MSCI data is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such.

Morningstar

Copyright © Morningstar Benelux. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results. For more information on Morningstar, please refer to www.morningstar.com

Febelfin disclaimer

The fact that the sub-fund has obtained this label does not mean that it meets your personal sustainability goals or that the label is in line with requirements arising from any future national or European rules. The label obtained is valid for one year and subject to annual reappraisal. For further information on this label, please visit www.towardsustainability.be.



Disclaimer

This document is exclusively distributed in Switzerland to qualified investors as such terms are defined under the Swiss Collective Investment Schemes Act (CISA) by ACOLIN Fund Services AG which is authorized by the Swiss Financial Market Supervisory Authority FINMA as Swiss representative of the Fund(s) and UBS Switzerland AG, Bahnhofstrasse 45, 8001 Zürich, postal address: Europastrasse 2, P.O. Box, CH-8152 Opfikon, as Swiss paying agent. The Prospectus, the Key Information Documents (PRIIPS), the Articles of Association, the annual and semi-annual reports of the Fund(s), as well as the list of the purchases and sales which the Fund(s) has undertaken during the financial year, may be obtained, on simple request and free of charge, at the head office of the Swiss representative ACOLIN Fund Services AG, Maintower Thurgauerstrasse 36/38 8050 Zurich, Switzerland. If the currency in which the past performance is displayed differs from the currency of the country in which you reside, then you should be aware that due to exchange rate fluctuations the performance shown may increase or decrease if converted into your local currency. The value of the investments may fluctuate. Past performance is no guarantee of future results. The performance data do not take account of the commissions and costs incurred on the issue and redemption of units. Unless otherwise stated, performances are i) net of fees based on transaction prices and ii) with dividends reinvested. Please refer to the prospectus of the funds for further details. The prospectus can be obtained free of charge from the representative and are available. The ongoing charges mentioned in this publication is the one stated in the fund's latest annual report at closing date of the last calendar year. The material and information in this document are provided "as is" and without warranties of any kind, either expressed or implied. ACOLIN Fund Services AG and its related, affiliated and subsidiary companies disclaim all warranties, expressed or implied, including, but not limited to, implied warranties of merchantability and fitness for a particular purpose. All information contained in this document is distributed with the understanding that the authors, publishers and distributors are not rendering legal, accounting or other professional advice or opinions on specific facts or matters and accordingly assume no liability whatsoever in connection with its use. In no event shall ACOLIN Fund Services AG and its related, affiliated and subsidiary companies be liable for any direct, indirect, special, incidental or consequential damages arising out of the use of any opinion or information expressly or implicitly contained in this document. Robeco Institutional Asset Management B.V. (Robeco) has a license as manager of Undertakings for Collective Investment in Transferable Securities (UCITS) and Alternative Investment Funds (AIFs) ("Fund(s)") from The Netherlands Authority for the Financial Markets in Amsterdam. Robeco is subject to limited regulation in the UK by the Financial Conduct Authority. Details about the extent of our regulation by the Financial Conduct Authority are available from us on request.